Furthermore, a novel triple receptor agonist peptide (retatrutide) that targets the glucagon receptor, the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the GLP-1R has been developed with the potential to treat metabolic abnormalities associated with obesity as well as diseases resulting from it due to its distinct mechanism of action [179]. Here, GLP1R is linked to obesity disorder.